ThomasCarlAndersonMD

Oncology • Bedford, TX

Practice leader and site research leader Texas Oncology

Join to view full profile

Dr. Anderson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Anderson's full profile

Already have an account?

Office
1615 Hospital Pkwy
Ste 300
Bedford, TX 76022
Phone+1 817-359-9000

Fax+1 817-359-9062

Education & Training

University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1978 - 1980
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1974 - 1977
University of Illinois College of MedicineClass of 1974

Certifications & Licensure

AZ State Medical License 1977 - Present
FL State Medical License 1977 - Present
TX State Medical License 1993 - 2022
NM State Medical License 1984 - 2000
WI State Medical License 1980 - 1985

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Start of enrollment: 2010 Oct 21
Terminated
Phase 4
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01
Completed
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
Completed
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member